Serum Intact Fibroblast Growth Factor 23 in Healthy Paediatric Population

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2021 Jul 14

PMID 34258392

Citations 7

Authors

Malgorzata Stanczyk

Slawomir Chrul

Krystyna Wyka

Marcin Tkaczyk

Affiliations

Soon will be listed here.

Abstract

Introduction: It is believed that fibroblast growth factor 23 (FGF23) can become an early biomarker of chronic kidney disease progression. Data on FGF23 age dependency are inconsistent. We present the results of the cross-sectional study concerning FGF23 levels in healthy Polish children.

Material And Methods: This study was conducted in 121 children aged 0-18 years. Kidney function and intact FGF23 levels in serum were assessed. Differences between age groups and according to gender were analysed.

Results: The difference in FGF23 between age groups and according to gender was statistically insignificant. In the youngest and the oldest group, a trend to higher FGF23 levels was observed. FGF23 level in girls tended to be higher than boys, apart from the age group between 1 and 4 years. There was a negative correlation between eGFR and FGF23 ( = -0.26, < 0.05) - strong in girls ( = -0.38, < 0.05), but not in boys. In each age group, we found no significant correlation between eGFR and FGF23.

Conclusions: Our study supports the evidence that the FGF23 level in paediatric population is not age or sex dependent. The results can serve as a reference point under clinical conditions and for other studies on the topic.

Citing Articles

Intact FGF23 and Markers of Iron Homeostasis, Inflammation, and Bone Mineral Metabolism in Acute Pediatric Infections.

Papastergiou E, Rallis D, Papagianni A, Cholevas V, Katzilakis N, Siomou E Biology (Basel). 2024; 13(9).

PMID: 39336155 PMC: 11428972. DOI: 10.3390/biology13090728.

Emerging concepts on the FGF23 regulation and activity.

Rivoira M, Peralta Lopez M, Areco V, Diaz de Barboza G, Dionisi M, Tolosa de Talamoni N Mol Cell Biochem. 2024; 480(1):75-89.

PMID: 38581553 DOI: 10.1007/s11010-024-04982-6.

[Clinical study on growth impairment induced by oral glucocorticoids based on FGF23/Klotho homeostasis observations].

Tang S, Yang Y, Li X, Bie B, Zhang J Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(3):269-274.

PMID: 38557379 PMC: 10986375. DOI: 10.7499/j.issn.1008-8830.2309160.

Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets.

Baroncelli G, Sessa M, Pelosini C, Bertelloni S, Michelucci A, Toschi B J Endocrinol Invest. 2023; 47(4):873-882.

PMID: 37991698 PMC: 10965647. DOI: 10.1007/s40618-023-02202-4.

FGF23 level in poultry chicken, a systematic review and meta-analysis.

Poorhemati H, Ghaly M, Sadvakassova G, Komarova S Front Physiol. 2023; 14:1279204.

PMID: 37908340 PMC: 10614003. DOI: 10.3389/fphys.2023.1279204.

References

Fischer D, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G . Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem. 2012; 49(Pt 6):546-53. DOI: 10.1258/acb.2012.011274. View

Braithwaite V, Prentice A, Doherty C, Prentice A . FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol. 2012; 2012(1):27. PMC: 3523041. DOI: 10.1186/1687-9856-2012-27. View

Ziolkowska H, Okarska-Napierala M, Stelmaszczyk-Emmel A, Gorska E, Zachwieja K, Zurowska A . Serum fibroblast growth factor 23 and calcium-phosphorus metabolism parameters in children with chronic kidney disease - preliminary report. Dev Period Med. 2014; 18(2):194-202. View

Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K . Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002; 143(8):3179-82. DOI: 10.1210/endo.143.8.8795. View

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

Braithwaite V, Jarjou L, Goldberg G, Prentice A . Iron status and fibroblast growth factor-23 in Gambian children. Bone. 2012; 50(6):1351-6. PMC: 3360160. DOI: 10.1016/j.bone.2012.03.010. View

Bergwitz C, Juppner H . Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010; 61:91-104. PMC: 4777331. DOI: 10.1146/annurev.med.051308.111339. View

Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S . Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001; 98(11):6500-5. PMC: 33497. DOI: 10.1073/pnas.101545198. View

Jonsson K, Zahradnik R, Larsson T, White K, Sugimoto T, Imanishi Y . Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003; 348(17):1656-63. DOI: 10.1056/NEJMoa020881. View

10.

Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K . Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444(7120):770-4. DOI: 10.1038/nature05315. View

11.

Gattineni J, Baum M . Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism. Pediatr Nephrol. 2009; 25(4):591-601. PMC: 3151467. DOI: 10.1007/s00467-009-1273-z. View

12.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y . FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3):429-35. DOI: 10.1359/JBMR.0301264. View

13.

Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson K . Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195(1):125-31. DOI: 10.1677/JOE-07-0267. View

14.

Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S . The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010; 95(4):1741-8. DOI: 10.1210/jc.2009-1576. View

15.

Devaraj S, Duncan-Staley C, Jialal I . Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease. Metab Syndr Relat Disord. 2010; 8(6):477-82. PMC: 3125567. DOI: 10.1089/met.2010.0030. View

16.

Ix J, Shlipak M, Wassel C, Whooley M . Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2009; 25(3):993-7. PMC: 2902926. DOI: 10.1093/ndt/gfp699. View

17.

Berndt T, Thomas L, Craig T, Sommer S, Li X, Bergstralh E . Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A. 2007; 104(26):11085-90. PMC: 1891094. DOI: 10.1073/pnas.0704446104. View

18.

Giral H, Caldas Y, Sutherland E, Wilson P, Breusegem S, Barry N . Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate. Am J Physiol Renal Physiol. 2009; 297(5):F1466-75. PMC: 2781338. DOI: 10.1152/ajprenal.00279.2009. View

19.

Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke H, Choukroun G . FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2011; 23(7):2017-25. DOI: 10.1007/s00198-011-1838-0. View

20.

. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-8. DOI: 10.1038/81664. View